Clariant, a global specialty chemicals leader, has announced the completion of its state-of-the-art facility expansion at Daya Bay, China. This strategic CHF 80-million investment marks a significant milestone in Clariant's Asia growth strategy, enhancing its manufacturing capacity, supply resilience, and product portfolio for pharmaceutical excipients and specialty chemicals.
The development responds to rising demand from Asia's pharmaceutical, personal care, and home care sectors, strengthening Clariant's commitment to quality, innovation, and regional partnership.
The newly expanded Daya Bay site features a second spray tower dedicated to pharmaceutical excipient production, specifically designed to serve customers in southern China. This tower enables greater consistency in manufacturing Active Pharmaceutical Ingredients (APIs) used in laxatives and various excipients essential for drug formulation.
As China’s pharma sector rapidly evolves, Clariant’s enhanced capabilities ensure the company plays an increasingly vital role in supporting drug makers with ingredients that meet stringent quality standards and regulatory compliance.
This expansion complements Clariant’s multi-purpose plant (MPP), which now houses an added reactor to support higher output of specialized chemicals. These include mild surfactants for personal care brands and soil release polymers for home care applications under Clariant’s Texcare range. Increased capacity aligns with rising demand for gentle, high-performance personal care goods and advanced home cleaning solutions in Asia. By centralizing these technologies in China, Clariant improves access for its regional clients, enabling more rapid development cycles and collaborative innovation tailored to local consumer needs.
In terms of sustainability and product performance, Daya Bay now produces a wider array of high-performance surfactants, such as water-based coatings that cut VOC emissions and synthetic lubricant ingredients that extend equipment lifespans.
